Yet another study has shown that the cyclopamine treatment can down-regulate expressions of CD44+ and CD133+ in gemcitabine-resistant pancreatic cancer cells indicating its potential efficacy in reversing gemcitabine resistance in pancreatic cancer [84]. This evidence concerns the gene PROM1 and familial pancreatic carcinoma.